These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30109143)

  • 1. Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment.
    Wang L; Peng W; Wu T; Deng P; Zhao YL
    Cell Death Discov; 2018; 4():24. PubMed ID: 30109143
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Muthu M; Kumar R; Syed Khaja AS; Gilthorpe JD; Persson JL; Nordström A
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
    Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
    Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
    Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
    Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy.
    Zhang W; Dong YZ; Du X; Peng XN; Shen QM
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2444-2452. PubMed ID: 30964170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous GLUL deletion is embryonically viable and leads to glutamine synthetase deficiency.
    Roifman M; Niles KM; MacNeil L; Blaser S; Noor A; Godoy R; van Mieghem T; Ryan G; Seaward G; Sondheimer N; Mercimek-Andrews S; Schulze A; Hewson S; Ovadia A; Chitayat D; Morgen EK; Hojilla C; Kolomietz E; Watkins N; Häberle J; Shannon P
    Clin Genet; 2020 Dec; 98(6):613-619. PubMed ID: 32888207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25-Dihydroxyvitamin D Regulation of Glutamine Synthetase and Glutamine Metabolism in Human Mammary Epithelial Cells.
    Beaudin S; Welsh J
    Endocrinology; 2017 Dec; 158(12):4174-4188. PubMed ID: 29029014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.
    Zhou L; Lv X; Yang J; Zhu Y; Wang Z; Xu T
    Oncol Lett; 2018 Aug; 16(2):2533-2538. PubMed ID: 30008942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-153 inhibits the resistance of lung cancer to gefitinib via modulating expression of ABCE1.
    Wang L; Lv X; Fu X; Su L; Yang T; Xu P
    Cancer Biomark; 2019; 25(4):361-369. PubMed ID: 31306106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
    Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
    PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-140-5p suppresses invasion and proliferation of glioma cells by targeting glutamate-ammonia ligase (GLUL).
    Zhang R; Zhu JC; Hu H; Lin QY; Shao W; Ji TH
    Neoplasma; 2020 Mar; 67(2):371-378. PubMed ID: 31986891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
    Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
    Koizumi F; Shimoyama T; Taguchi F; Saijo N; Nishio K
    Int J Cancer; 2005 Aug; 116(1):36-44. PubMed ID: 15761868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis.
    Jeong CH
    J Cancer Prev; 2015 Mar; 20(1):57-63. PubMed ID: 25853104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells.
    Ji Y; Ma SL; Zhang YP; Tang JJ; Wu YM; Lu YJ
    Anticancer Drugs; 2009 Oct; 20(9):832-7. PubMed ID: 19620837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
    Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
    Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
    Gong J; He L; Ma J; Zhang J; Wang L; Wang J
    J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
    Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
    Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamine synthetase activity and the expression of three glul paralogues in zebrafish during transport.
    Dhanasiri AK; Fernandes JM; Kiron V
    Comp Biochem Physiol B Biochem Mol Biol; 2012; 163(3-4):274-84. PubMed ID: 22750401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways.
    Wang X; Xu J; Chen J; Jin S; Yao J; Yu T; Wang W; Guo R
    Front Oncol; 2019; 9():1167. PubMed ID: 31750252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.